Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Diatos Completes a Series D €9.4 Million Private Financing Round

Paris, France, 03 July 2007 – Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, has announced the successful closing of a financing round raising €9.4 million. The round was led by existing investors of Diatos including GIMV (Belgium), Credit Agricole Private Equity (France), InterWest Partners (United States), Innoven Partenaires (France), Sofinnova Partners (France) and Biotech Fund Flanders (Belgium). Additional existing investors who also participated in the round included AGF Private Equity (France), NIF SMBC (Japan), Sopartec (Belgium), and SGAM (France). This brings the total equity capital raised by Diatos since its inception in 1999 to date to €54.8 million.

The new injection of funding will allow Diatos to further develop its leading clinical products at full capacity. These include paclitaxel depot formulated polymer gel DTS-301, recently completing a Phase IIa and now ready to enter Phase IIb/III in Esophageal cancer, and doxorubicin prodrug DTS 201, poised to enter Phase II. Diatos will focus on expanding its product pipeline with the launch of DTS-108, a promising second generation Irinotecan, currently in GLP preclinical toxicology studies, and on the continuous generation of new TSP-based drugs.

Commenting on the financing, Dr John Tchélingérian, President and CEO said: “We are delighted to have received this significant financial support from our world class investor group that continuously supported Diatos and its management team. The Company is now in a strong financial position with a deep and balanced portfolio of oncology products and assets. With this financing we will focus on taking our clinical and preclinical products forward to their next stage of maturity and achieve significant development and value creation milestones”.

– ends –

About Diatos

Diatos is a biopharmaceutical company dedicated to the research, development and commercialization of innovative anti-cancer drugs with enhanced tumor targeting or improved biodistribution. Diatos is expanding its portfolio of drug candidates with new compounds that utilize its Vectocell® delivery technology or its Tumor-Selective Prodrug (TSP) technology as well as with in-licensed candidate and marketed cancer therapies. Diatos is headquartered in Paris, France and operates subsidiaries in Belgium and the United States of America.

About Diatos’ Portfolio

> DaunoXome®, a liposomal formulation of widely used cancer drug daunorubicin, improves the biodistribution of daunorubicin and fosters its sustained release in the blood, which potentially allows the administration of higher doses than with non-liposomal formulations. DaunoXome is marketed in Kaposi’s sarcoma and is being re-launched in acute leukaemia in Europe. DaunoXome was in-licensed from Gilead Sciences, Inc.

> DTS-301, a paclitaxel depot formulation in the polymer gel ReGel®, releases paclitaxel, a widely used cancer drug, directly to the tumor site, avoiding systemic side effects. DTS-301 is in Phase II clinical stage and was in-licensed from Protherics PLC.

> DTS-201, a doxorubicin prodrug, increases the concentration of doxorubicin, a widely used cancer drug, at the tumor site by means of a reactivation mechanism specific to the tumor environment. DTS-201 has completed Phase I clinical studies in Belgium and France in Q2-07. Exclusive European rights for DTS-201 were in-licensed from Medarex Inc.

> DTS-108 is a prodrug of SN-38, the active metabolite of the widely-used cancer drug irinotecan, and is based on Diatos' Vectocell® technology. DTS-108 aims to increase the efficacy of SN-38 while reducing the toxic effects of irinotecan. DTS-108 is in preclinical development.

For further information please visit the website at

About AGF Private Equity –

AGF Private Equity, a subsidiary of the AGF Insurance Company, member of the Allia

Publisher Contact Information:

Diatos SA
+ 33 (0)1 53 80 93 81

Company profile of Diatos SA
Past press releases of Diatos SA.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.